J&J sales and marketing update

Germany’s Institute for Quality and Efficiency in Health Care (IQWiG) said in an dossier of early benefit assessment that an added benefit was not proven for Edurant rilpivirine to treat HIV-1 infection in children and adolescents ages 12 and older. The agency said Johnson & Johnson only presented data from a one-arm study and did not conduct any indirect comparison trials to comparator therapies. ...